MX2019014841A - Potencial antiobsesidad del garcinol. - Google Patents

Potencial antiobsesidad del garcinol.

Info

Publication number
MX2019014841A
MX2019014841A MX2019014841A MX2019014841A MX2019014841A MX 2019014841 A MX2019014841 A MX 2019014841A MX 2019014841 A MX2019014841 A MX 2019014841A MX 2019014841 A MX2019014841 A MX 2019014841A MX 2019014841 A MX2019014841 A MX 2019014841A
Authority
MX
Mexico
Prior art keywords
garcinol
disclosed
obesity
management
obesity potential
Prior art date
Application number
MX2019014841A
Other languages
English (en)
Inventor
Majeed Muhammed
Nagabhushanam Kalyanam
Mundkur Lakshmi
Original Assignee
Sami Labs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Labs Ltd filed Critical Sami Labs Ltd
Publication of MX2019014841A publication Critical patent/MX2019014841A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Confectionery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen composiciones que contienen Garcinol para el tratamiento terapéutico de la obesidad. Más especificamente, la invención se refiere al uso de Garcinol para a) mantenimiento del equilibrio energético en sistemas celulares adiposos de mamíferos b) el manejo de la hipercolesterolemia y c) la reducción del aumento de peso en mamíferos. También se describe la modificación de la microbiota intestinal y el aumento del microbio beneficioso, Akkermansia muciniphila por el Garcinol.
MX2019014841A 2017-06-15 2018-06-13 Potencial antiobsesidad del garcinol. MX2019014841A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762519949P 2017-06-15 2017-06-15
US201762523611P 2017-06-22 2017-06-22
PCT/US2018/037242 WO2018231923A1 (en) 2017-06-15 2018-06-13 Anti-obesity potential of garcinol

Publications (1)

Publication Number Publication Date
MX2019014841A true MX2019014841A (es) 2020-02-17

Family

ID=64659462

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014841A MX2019014841A (es) 2017-06-15 2018-06-13 Potencial antiobsesidad del garcinol.

Country Status (8)

Country Link
EP (1) EP3638226A4 (es)
JP (3) JP2020523373A (es)
KR (1) KR102289324B1 (es)
AU (1) AU2018284354A1 (es)
BR (1) BR112019026824A2 (es)
CA (1) CA3066446A1 (es)
MX (1) MX2019014841A (es)
WO (1) WO2018231923A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102136335B1 (ko) * 2020-03-24 2020-07-22 (주)메디톡스 간기능 개선 또는 지방축적 억제 미생물 및 그의 용도
KR102363094B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 간질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 간질환 예방 또는 치료제 스크리닝 방법
KR102191487B1 (ko) * 2020-06-19 2020-12-15 (주)메디톡스 간기능 개선 또는 지방축적 억제 미생물 및 그의 용도
KR102363092B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 비만 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 비만 예방 또는 치료제 스크리닝 방법
KR102363098B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 신질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 신질환 예방 또는 치료제 스크리닝 방법
KR102363088B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 당뇨병 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 당뇨병 예방 또는 치료제 스크리닝 방법
KR102331485B1 (ko) 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN114605242A (zh) * 2022-04-11 2022-06-10 澳门大学 间苯三酚类化合物的制备方法与药物、保健产品和食品
CN114847475B (zh) * 2022-07-05 2022-11-29 广东金骏康生物技术有限公司 一种促进akk菌生长的发酵槐米粉的应用
CN115637242A (zh) * 2022-10-20 2023-01-24 中南大学 微生物复合菌剂及其制备方法和赤泥原位生物脱碱的方法
CN116903760A (zh) * 2023-05-25 2023-10-20 浙江大学 木耳多糖及其制备方法和抑制肥胖的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000044468A (ja) * 1998-07-29 2000-02-15 Kikkoman Corp リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤
US7063861B2 (en) * 2000-08-17 2006-06-20 Sabinsa Corporation Bioavailable composition of natural and synthetic HCA
AU2011352073B2 (en) 2010-12-30 2015-12-24 Sami Labs Limited Hepatoprotectant activity of garcinol
US8329743B2 (en) * 2011-01-10 2012-12-11 Sami Labs Limited Compositions and its use in treating obesity or inducing weight loss
CA3092318A1 (en) * 2012-09-20 2014-03-27 Prothera, Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
US9872840B2 (en) * 2013-10-03 2018-01-23 Delhi Institute Of Pharmaceutical Sciences And Research Effect of garcinol in delaying the progression of diabetic nephropathy
US10300085B2 (en) * 2014-03-24 2019-05-28 Daicel Corporation Nutritional composition
CA2934156A1 (en) * 2015-11-10 2017-05-10 Muhammed Majeed Use of forskolin in the treatment of obesity

Also Published As

Publication number Publication date
JP2020523373A (ja) 2020-08-06
CA3066446A1 (en) 2018-12-20
BR112019026824A2 (pt) 2020-06-30
JP2022097521A (ja) 2022-06-30
KR20200012978A (ko) 2020-02-05
KR102289324B1 (ko) 2021-08-12
AU2018284354A1 (en) 2020-01-16
WO2018231923A1 (en) 2018-12-20
JP2021185156A (ja) 2021-12-09
EP3638226A4 (en) 2021-04-07
EP3638226A1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
MX2019014841A (es) Potencial antiobsesidad del garcinol.
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
BR112018008442A2 (pt) receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
CR20200601A (es) Anticuerpos biespecificos contra dll3-cd3
MX2019003616A (es) Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas.
EP4036240A3 (en) Transduction buffer
PH12020500677A1 (en) Neoantigens and uses thereof
MX2016011132A (es) Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
SG10201906304TA (en) Use of perfusion decellularized liver for islet cell recellularization
MX2013014544A (es) Vectorales de terapia genica para adrenoleucodistrofia y adrenomieloneuropatia.
EA201790293A2 (ru) Антитела, направленные против icos, и их применения
ZA201805792B (en) Taurine and aloe synergistic anti-irritant compositions and methods
MX2013008702A (es) Composiciones que contienen anticuerpos glicosilados y sus usos.
AU2016335217A8 (en) Antigen receptors and uses thereof
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
WO2018088694A3 (ko) 인위적으로 조작된 sc 기능 조절 시스템
EA201690680A1 (ru) Комбинированное противоопухолевое лечение с применением миниклеток, загруженных лекарственным средством, нацеленных с использованием биспецифического лиганда, и интерферона-гамма
MX2020004063A (es) Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
WO2018170150A3 (en) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
MX2019009604A (es) Composicion quimica.
WO2021044373A3 (en) Engineering of immune cells for ex vivo cell therapy applications
MX2022007391A (es) Compuestos activos frente a receptores nucleares.